Credit: Sundry Photography via Shutterstock. Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations” ...

Read the Market Summary Here @- Global Cardiac Resynchronization Therapy (CRT) Devices Market Size Booming at Healthy CAGR of 8.4% to Touch USD 11.6 Billion by 2030 Global Cardiac Resynchronization ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy. Now, it has resumed its work to see whether its Farapulse platform can ...

Exposure to temperatures of 100°F (38°C) or higher may nearly triple the number of episodes of a form of irregular heart ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Exposure to extreme heat may double or triple the risk of irregular heart rhythms in people with implanted defibrillators, ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Severe temperature spikes may double or triple the risk of irregular heart rhythm in people with implanted defibrillators. An analysis of health data for more than 2,000 people with implantable ...

TMOThermo Fisher Scientific Inc.